Начало・Списък с акции・AbbVie Inc

AbbVie Inc

Отворен

СекторЗдравеопазване

243.69 -0.44

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

242.53

Максимум

247.63

Ключови измерители
By Trading Economics
Приходи	-1.1B 697M
Продажби	-1.6B 15B
P/E Средно за сектора	126.557 64.641
EPS	2.65
Дивидентна доходност	2.6
Марж на печалбата	4.646
Служители	57,000
EBITDA	-1.7B 3.7B

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+12.63% upside

Дивиденти
By Acuity
Дивидентна доходност Средно за сектора	2.60% 2.31%
Следващи печалби	30.10.2026 г.
Следваща дата на дивидент	14.08.2026 г.
Следваща дата на екс-дивидент	14.10.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	105B 454B
Предишно отваряне	244.13
Предишно затваряне	243.69

Настроения в новините

By Acuity

18%

82%

36 / 340 Класиране в Healthcare

AbbVie Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.08.2026 г., 23:06 ч. UTC

News

Canaccord Genuity raised its price target for AbbVie to $290, contributing to a modest increase in shares during after-market hours.

31.07.2026 г., 20:04 ч. UTC

News

Event

AbbVie Inc. lowered its 2026 adjusted earnings guidance, now projecting $13.87 to $14.07 per share, contributing to a decline in its stock price today.

30.07.2026 г., 22:41 ч. UTC

Social Media

Event

AbbVie Inc announced JUVÉDERM® Day for August 19, 2026, boosting shares higher in after-market hours amid strong trading activity.

29.07.2026 г., 23:06 ч. UTC

Event

The European Commission approved RINVOQ® for severe alopecia areata, contributing to higher after-market hours trading for Abbvie Inc. Shares remain above their 20-day moving average.

28.07.2026 г., 23:06 ч. UTC

AbbVie Inc. shares traded higher in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

27.07.2026 г., 19:46 ч. UTC

Social Media

AbbVie Inc. shares are trading lower amid a broader market decline, influenced by falling crude oil prices despite recent social media discussions on its 52-week high.

24.07.2026 г., 23:51 ч. UTC

Social Media

Abbvie shares are trading lower in after-market hours despite a presentation on ABBV-CLS-484, a novel cancer immunotherapy inhibitor.

23.07.2026 г., 10:16 ч. UTC

AbbVie Inc shares are trading lower in pre-market hours, with no specific news identified to explain the movement. The stock remains within its one-month trading range.

22.07.2026 г., 23:06 ч. UTC

AbbVie Inc shares are modestly higher in after-market trading. No specific news was identified to explain the movement, amid broader market volatility.

21.07.2026 г., 19:06 ч. UTC

Abbvie Inc. is higher today, supported by broader market gains and optimism in the semiconductor sector after TSMC's potential price increases by 2027.

20.07.2026 г., 23:01 ч. UTC

AbbVie Inc. shares are lower in after-hours trading following a decline from earlier gains, remaining above the 20-day moving average.

Сравнение с други в отрасъла

Ценова промяна

AbbVie Inc Прогноза

Ценова цел

By TipRanks

12.63% нагоре

12-месечна прогноза

Среден 276.05 USD 12.63%

Висок 300 USD

Нисък 225 USD

Според 22 анализатори от Wall Street, предложили 12-месечна ценова цел за AbbVie Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

22 ratings

Купи

Задържане

Продай

Според 22 анализатори, дали борсови рейтинги на AbbVie Inc през последните 3 месеца.

Настроение

By Acuity

36 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.